Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers

Biomarkers

Volumn 18, Issue 6, 2013, Pages 532-541

  Hariprasad, Gururao ^a   Hariprasad, Roopa ^a   Kumar, Lalit ^a   Srinivasan, Alagiri ^a   Kola, Srujana ^a   Kaushik, Amit ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Gel based proteomics; metastatic ovarian cancer; primary ovarian cancer; validation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; FAS ANTIBODY; PROGRAMMED DEATH 1 LIGAND 2;

ADVANCED CANCER; ARTICLE; ASCITES FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATIENT CARE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; WESTERN BLOTTING;

APOLIPOPROTEIN A-I; ASCITIC FLUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885215930     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.822561     Document Type: Article

References (60)

1. Aboulghar MA, Mansour RT, Serour GI, et al. (1999). Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 87: 81-5.
2. Abramoff MD, Magalhaes PJ, Ram SJ. (2004). Image processing with ImageJ. Biophoton Int 11:36-42.
3. Achariyapota V, Benjapibal M, Chaopotong P. (2010). Prevalence and incidence of anemia in Thai patients with gynecologic cancer. Asian Pac J Cancer Prev 11:1229-33.
4. Agata Y, Kawasaki A, Nishimura H, et al. (1996). Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765-72.
5. Barton DP, Blanchard DK, Michelini-Norris B, et al. (1993). High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer. Blood 81:424-9.
6. Brahmer JR, Tykodi SS, Chow LQ, et al. (2012). Safety and activity of anti-PD-L1 antibody in-patients with advanced cancer. N Engl J Med 366:2455-65.
7. Candiano G, Bruschi M, Musante L, et al. (2004). Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 25:1327-33.
8. Colombo N, Peiretti M, Parma G, et al.; ESMO Guidelines Working Group. (2010). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v23-30.
9. de Waal YR, Thomas CM, Oei AL, et al. (2009). Ovarian metastasis from a non-ovarian cancer ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer 19:1160-5.
10. Falchook GS, Wolff RA, Varadhachary GR. (2008). Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol 108:515-19.
11. Freeman GJ, Long AJ, Iwai Y, et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-34.
12. Ganapathy E, Su F, Meriwether D, et al. (2012). D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer 130:1071-81.
13. Gao F, Vasquez SX, Su F, et al. (2011). sL-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) 3:479-89.
14. Ghiotto M, Gauthier L, Serriari N, et al. (2010). PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 22:651-60.
15. Goldberg IJ, Scheraldi CA, Yacoub LK, et al. (1990). Lipoprotein ApoC-II activation of lipoprotein lipase modulation by apolipoprotein A-IV. J Biol Chem 265:4266-72.
16. Guney S, Guney N, Ozcan D, et al. (2010). Ovarian metastasis of a primary renal cell carcinoma: case report and review of literature. Eur J Gynaecol Oncol 31:339-41.
17. Hachem H, Favre G, Raynal G, et al. (1986). Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis. J Clin Chem Clin Biochem 24: 161-6.
18. Hamanishi J, Mandai M, Iwasaki M, et al. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360-5.
19. Hariprasad G, Srinivasan A, Vedakumari Y. (2011). Electrical conductivity as a tool to detect salt in clinical proteomics samples. Indian J Clin Biochem 26:82-3.
20. Hart WR. (2005). Diagnostic challenge of ovarian metastasis from a nonovarian cancer (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int 55:231-43.
21. Hashimoto YN, Yamamoto T, Kamiura S, et al. (2003). Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol 89:314-17.
22. Hoskins P, Vergote I, Cervantes A, et al. (2010). Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 102:1547-56.
23. Hristov AC, Young RH, Vang R, et al. (2007). Ovarian metastases of appendiceal tumors with goblet cell carcinoid like and signet ring cell patterns: a report of 30 cases. Am J Surg Pathol 31:1502-11.
24. Igney FH, Krammer PH. (2005). Tumor counterattack: fact or fiction? Cancer Immunol Immunother 54:1127-36
25. Imamura H, Kishimoto T, Kawabata R, et al. (2010). A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection. Gan To Kagaku Ryoho 37:2490-2.
26. Ishida Y, Agata Y, Shibahara K, Honjo T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887-95.
27. Januszewska M, Emerich J, Dibniak J, et al. (2006). Clinical analysis of patients with Krukenberg tumor of the ovary. Ginekol Pol 77:203-8.
28. Jain V, Gupta K, Kudva R, Rodrigues GS. (2006). A case of ovarian metastasis of gall bladder carcinoma simulating primary ovarianneoplasm: diagnostic pitfalls and review of literature. Int J Gynecol Cancer 16:319-21.
29. Jemal A, Tiwari RC, Murray T, et al.; American Cancer Society. (2004). Cancer statistics. CA Cancer J Clin 54:8-29.
30. Jemal A, Siegel R, Ward E, et al. (2009). Cancer statistics. CA Cancer J Clin 59:225-49.
31. Jin JS, Yao CW, Loh SH, et al. (2004). Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol 25:140-6.
32. Kawakubo N, Okido M, Tanaka R, et al. (2010). Pseudo-Meigs' syndrome associated with breast cancer metastasis to both ovaries: report of a case. Surg Today 40:1148-51.
33. Khunamornpong S, Siriaunkgul S, Suprasert P, et al. (2007). Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of ovarian metastasis from a non-ovarian cancer tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol 31:1788-99.
34. Khunamornpong S, Lerwill MF, Siriaunkgul S, et al. (2008). Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol 27:366-79.
35. Ketata W, Msaad S, Feki W, et al. (2011). Ovarian metastasis from bronchial carcinoma. Rev Mal Respir 28:101-5.
36. Konishi J, Yamazaki K, Azuma M, et al. (2004). B7-H1 expression on non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10:5094-100.
37. Latchman Y, Wood CR, Chernova T, et al. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261-8.
38. Ledermann JA. (2010). Primary chemotherapy: the future for the management of advanced ovarian cancer? Int J Gynecol Cancer 20: S17-19
39. Lee KR, Young RH. (2003). The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 27:281-92.
40. Lerwill MF, Young RH. (2006). Ovarian metastases of intestinal-type gastric carcinoma: a clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor.AmJ Surg Pathol 30:1382-8.
41. Li ZG, Zhao L, Liu L, Ding YQ. (2007). Monitoring changes of serum protein markers in metastatic colorectal carcinoma model. Zhonghua Bing Li Xue Za Zhi 36:48-52.
42. Mata JM, Inaraja L, Rams A, et al. (1988). CT findings in metastatic ovarian tumors from gastrointestinal tract neoplasms (Krukenberg tumors). Gastrointest Radiol 13:242-6.
43. Mann B, Gratchev A, Böhm C, et al. (1999). FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79:1262-9.
44. Megibow AJ, Hulnick DH, Bosniak MA, Balthazar EJ. (1985). Ovarian metastases: computed tomographic appearances. Radiology 156: 161-4.
45. Mizumoto H, Saito T, Ashihara K, et al. (2002). Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci 71:259-73.
46. Mukai M, Moriya H, Himeno S, et al. (2001). Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases. Oncol Rep 8:79-83.
47. Ohigashi Y, Sho M, Yamada Y, et al. (2005). Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947-53.
48. Okazaki T, Maeda A, Nishimura H, et al. (2001). PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting SRC homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98:13866-71.
49. Pedersen N, Schmitt M, Rønne E, et al. (1993). A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92:2160-7.
50. Shiraki K, Tsuji N, Shioda T, et al. (1997). Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94:6420-5.
51. Su F, Kozak KR, Imaizumi S, et al. (2010). Apolipoprotein A-I (apoAI) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 107: 19997-20002.
52. Takagi T, Nakase Y, Fukumoto K, et al. (2009). A patient with metachronous ovarian metastases of signet-ring cell carcinoma of the transverse colon showing long-term survival after surgery. Gan To Kagaku Ryoho 36:2260-2.
53. Topalian SL, Hodi FS, Brahmer JR, et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54.
54. Tso P, Liu M, Kalogeris TJ, Thomson AB. (2001). The role of apolipoprotein A-IV in the regulation of food intake. Annu Rev Nutr 21:231-54.
55. Ulbright TM, Roth LM, Stehman FB. (1984). Ovarian metastasis from a non-ovarian cancer ovarian neoplasia: a clinicopathologic study of 35 cases. Cancer 53:1164-74.
56. Xu LN, Zou SQ, Wang JM. (2005). Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. World J Gastroenterol 11:3719-23.
57. Young RH. (2007). From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 14:149-77.
58. Zhang B, Cai FF, Zhong XY. (2011). An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol 158: 119-23.
59. Zhao JZ, Wang G, Zhang RP, Liang H. (2010). Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 13: 129-32.
60. Zheng HC, Sun JM, Wei ZL, et al. (2003). Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol 9:1415-20.